TEK
Angiopoietin-1 receptor
As of the edition of 20 October 2026, TEK (angiopoietin-1 receptor, UniProt Q02763) has 8 drugs tested at it and 8 companies on the list, 3 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q02763
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 17
- Disease areas
- Cancer; Digestive system; Lungs and airways; Urinary and reproductive; Hormones; Pregnancy and women's health; Skin and connective tissue; Blood and lymph
- Registered trials of its drugs
- 286
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 3 |
| Status not established | 2 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Regorafenib | Marketed | Phase 4 | Ends 2032 |
| Foretinib | Active | Phase 3 | none listed |
| Glesatinib | Stopped | Phase 2 | none listed |
| CEP-11981 | Stopped | Phase 2 | none listed |
| AV-001 | Went quiet | Phase 1 | none listed |
| Altiratinib | Stopped | Phase 1 | none listed |
| PMC-403 | Status not established | Phase 1 | none listed |
| Pexmetinib | Status not established | Phase 2 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 1 |
| Engaged | 2 |
| Undetermined | 2 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route A |
| Bayer | Route B |
| Deciphera Pharmaceuticals | Route A |
The other 5 companies at TEK
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at TEK, ranked, with the facts behind eachRequest access. Nothing is shown until you do.